Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$37.50 -0.6%	$37.86	$27.34 ▼ $59.62	$6.89B	0.26	1.13 million shs	869,003 shs
RVMD Revolution Medicines	$36.32 +0.8%	$37.93	$29.17 ▼ $62.40	$6.79B	1.16	1.85 million shs	1.39 million shs
RYTM Rhythm Pharmaceuticals	$97.61 +1.2%	$78.46	$43.57 ▼ $99.04	$6.48B	2.38	579,718 shs	522,257 shs
VCEL Vericel	$36.28 +1.4%	$39.72	$33.09 ▼ $63.00	$1.83B	1.27	633,788 shs	654,735 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	0.00%	+1.35%	-9.83%	+28.82%	-34.08%
RVMD Revolution Medicines	0.00%	+3.77%	-5.17%	-9.04%	-15.24%
RYTM Rhythm Pharmaceuticals	0.00%	+6.12%	+9.43%	+59.36%	+111.83%
VCEL Vericel	0.00%	+0.11%	+2.66%	-14.72%	-21.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LEGN Legend Biotech	3.7261 of 5 stars	4.5	4.0	0.0	2.4	1.7	0.6
RVMD Revolution Medicines	4.1709 of 5 stars	4.5	1.0	4.7	2.0	1.7	0.0
RYTM Rhythm Pharmaceuticals	3.7419 of 5 stars	2.5	3.0	4.3	3.3	0.8	0.6
VCEL Vericel	2.3055 of 5 stars	3.5	0.0	0.0	3.1	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	3.00	Buy	$72.38	93.00% Upside
RVMD Revolution Medicines	3.00	Buy	$68.67	89.06% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$101.57	4.06% Upside
VCEL Vericel	3.00	Buy	$60.33	66.30% Upside

Current Analyst Ratings Breakdown

Latest VCEL, LEGN, RVMD, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	RVMD Revolution Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$67.00
8/12/2025	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$75.00 ➝ $77.00
8/12/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$81.00 ➝ $83.00
8/7/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$57.00 ➝ $56.00
8/7/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $100.00
8/6/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$119.00 ➝ $120.00
8/6/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$130.00 ➝ $135.00
8/5/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$100.00 ➝ $109.00
8/4/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$627.24M	10.99	N/A	N/A	$5.70 per share	6.58
RVMD Revolution Medicines	$11.58M	586.30	N/A	N/A	$13.47 per share	2.70
RYTM Rhythm Pharmaceuticals	$130.13M	49.82	N/A	N/A	$0.35 per share	278.89
VCEL Vericel	$249.12M	7.35	$0.31 per share	116.10	$5.92 per share	6.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$177.03M	-$0.88	N/A	N/A	N/A	-40.83%	-32.00%	-20.07%	N/A
RVMD Revolution Medicines	-$600.09M	-$4.50	N/A	N/A	N/A	N/A	-41.78%	-35.63%	11/5/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$3.01	N/A	N/A	N/A	-117.13%	-1,831.43%	-48.33%	11/4/2025 (Estimated)
VCEL Vericel	$10.36M	$0.12	302.36	82.45	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest VCEL, LEGN, RVMD, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	LEGN Legend Biotech	-$0.22	-$0.34	-$0.12	-$0.34	$237.49 million	$255.06 million
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$0.94	-$1.31	-$0.37	-$1.31	$0.50 million	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.66	-$0.75	-$0.09	-$0.75	$43.72 million	$48.50 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	0.30	4.71	4.57
RVMD Revolution Medicines	0.13	11.79	11.79
RYTM Rhythm Pharmaceuticals	N/A	2.79	2.64
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
RVMD Revolution Medicines	94.34%
RYTM Rhythm Pharmaceuticals	N/A
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
RVMD Revolution Medicines	8.20%
RYTM Rhythm Pharmaceuticals	6.10%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
RVMD Revolution Medicines	250	186.93 million	171.60 million	Optionable
RYTM Rhythm Pharmaceuticals	140	66.42 million	62.37 million	Optionable
VCEL Vericel	300	50.46 million	46.83 million	Optionable

VCEL, LEGN, RVMD, and RYTM Headlines

Recent News About These Companies

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17 at 5:31 AM | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1, 2025 | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1, 2025 | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1, 2025 | finance.yahoo.com

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Vericel Corporation Reports Strong Q2 2025 Results

July 31, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, LEGN, RVMD, and RYTM Company Descriptions

Legend Biotech NASDAQ:LEGN

$37.50 -0.21 (-0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$37.40 -0.10 (-0.26%)

As of 08/15/2025 07:57 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Revolution Medicines NASDAQ:RVMD

$36.32 +0.30 (+0.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$36.32 0.00 (0.00%)

As of 08/15/2025 04:34 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$97.61 +1.13 (+1.17%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$95.50 -2.11 (-2.17%)

As of 08/15/2025 06:27 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Vericel NASDAQ:VCEL

$36.28 +0.51 (+1.43%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$36.28 -0.01 (-0.01%)

As of 08/15/2025 04:54 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time